Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences : buys US firm Kite Pharma for $11.9bn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:14pm CET

Biopharmaceutical company Gilead Sciences has completed the acquisition of US-based Kite Pharma for approximately $11.9bn.

Kite Pharma specialises in the development of new cell therapies, which use a patients own immune cells to fight cancer.

Gilead Sciences has completed the transaction through Dodgers Merger Sub, a wholly owned subsidiary of the company.

On 28 August, the two companies entered a definitive merger agreement to complete the acquisition.

A tender offer was started on 5 September to buy all the outstanding shares of Kite Pharma at a price of $180 each.

Gilead Sciences has successfully concluded the tender offer for all of Kite Pharma`s common stock shares.

"Kite Pharma has become a wholly owned subsidiary of Gilead Sciences."

Gilead Sciences president and chief executive officer Dr John F Milligan said: Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them."

With the completion of the acquisition, Kite Pharma has become a wholly owned subsidiary of Gilead Sciences.

Bank of America Merrill Lynch, Lazard and Barclays acted as financial advisors to Gilead Sciences, while Skadden, Arps, Slate, Meagher and Flom served as the companys legal advisors.

Kite Pharma has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the form of cancer.

The companys major CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL).

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
12/14 GILEAD SCIENCES : Announces That John C. Martin, PhD Will Transition From Execut..
12/14 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
12/14 GILEAD SCIENCES : Kite Announces Data from ZUMA-3 Study of KTE-C19 in Adult Pati..
12/14 GILEAD SCIENCES : ex-dividend day
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/13 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/13 GILEAD SCIENCES : (GILD) Posts Updated Data on CAR-T Therapy Yescarta
12/12 GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
12/12 GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/11 GILEAD SCIENCES : Today’s Research Reports on Stocks to Watch: Gilead Sciences a..
More news
News from SeekingAlpha
12/14 Galapagos elects to co-promote filgotinib with Gilead in Europe
12/14 Did ASH Just Change The Juno Best In Class Thesis?
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/13 CONATUS : Likely To Dash Ahead Of NASH Data
12/13 Why Tech Still Looks So Attractive
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,76%
P/E ratio 2017 9,84
P/E ratio 2018 12,83
EV / Sales 2017 4,37x
EV / Sales 2018 4,95x
Capitalization 100 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES3.64%100 008
REGENERON PHARMACEUTICALS1.78%41 544
VERTEX PHARMACEUTICALS94.94%36 620
GENMAB0.85%10 225
BLUEBIRD BIO INC177.39%8 474
EXELIXIS, INC.80.42%7 864